[Market Pulse]Bio-Manufacturing Transition: The 'Synthetic Biology' to Watch
Korea Lagging Behind Major Countries in Technology and Policy
Need for Rebalancing Investment and Building an Integrated Ecosystem
Tae-Seok Oh, President of the Korea Institute of Science and Technology Planning and Evaluation
View original imageAt the beginning of this year, the rise of China's "Red Tech," symbolized by the "DeepSeek shock," has begun to spread across the entire field of advanced science and technology. China is achieving rapid results not only in artificial intelligence (AI) and autonomous driving, but also in the bioindustry. Since 2021, China has been pursuing its "14th Five-Year Plan for Bioeconomy Development," and is now recognized for quickly securing global competitiveness in numerous fields, including innovative new drugs, bio-based materials, and agricultural technology.
The United Kingdom, a powerhouse in the life sciences sector, announced its "National Engineering Biology Vision" in 2023 and declared an investment of 2 billion pounds. The United States, in response to the rise of Chinese companies, is pushing for the enactment of the "Biosecurity Law," while also expanding government-wide investments in biotechnology and manufacturing innovation.
Synthetic biology has now emerged as a technology that not only creates economic added value, but also underpins national security and strategic industries. As a result, advanced technology countries such as the United States, China, and Europe are managing it as a regulated technology subject to export controls. Synthetic biology views living organisms as "systems that can be designed," and refers to technologies that engineer the functions of DNA, proteins, and cells to create new traits not found in nature.
Much like assembling Lego blocks, this technology uses standardized DNA components to create desired biological functions, going beyond the traditional paradigm of biotechnology. Its applications are expanding broadly, from rare disease therapeutics, personalized medicines, and immune cell therapies, to white and green bio sectors such as carbon-capturing microorganisms, bioplastics, and artificial protein fibers.
Recently, as synthetic biology converges with AI technology, the speed and scope of innovation are expanding rapidly. This year, Korea became the first country in the world to enact the "Synthetic Biology Promotion Act," which is set to take effect next year. Korea is also expanding research and development investment in synthetic biology and is promoting the establishment of a national, government-led public biofoundry.
However, there remains a gap in technology level and industrialization speed compared to the United States, China, and Europe. The government has set a vision to convert 30% of petroleum-based manufacturing to bio-based manufacturing by 2030. However, given the structural changes in the petrochemical industry and the trend toward stronger carbon regulations, there is a need to accelerate the strategy for transitioning to bio-manufacturing.
The future direction of policy is clear. The government must expand the proportion of research and development investment, which has so far focused on red bio fields such as new drugs and medical devices, to include white and green bio sectors. It is also necessary to introduce a scale-up system based on technology readiness level (TRL) that reflects industrial demand, as well as performance-linked research and development models tailored to each product and material, in order to resolve the "industrialization bottleneck" that occurs after demonstration.
It is essential to accelerate the construction of biofoundries currently underway, expand specialized foundries in regional hubs, and create an integrated ecosystem where research, demonstration, and manufacturing are seamlessly connected. Above all, close collaboration is needed among demand industries such as petrochemicals, materials, and food, as well as government research institutes and universities.
Bio-manufacturing is not a new field exclusive to startups; it is a sector where economic impact and marketability are maximized only when linked to the structural transformation of existing industries. At the same time, regulations related to living modified organisms (LMOs), genetically modified organisms (GMOs), and gene editing must be rationally updated to keep pace with technological advances.
It would be desirable to first create cases of application that enhance social acceptance in relatively less sensitive fields such as medicine and non-food sectors, and then gradually expand this approach to more sensitive areas such as food and agriculture.
Synthetic biology is no longer a technology confined to the laboratory; it is a national strategic technology that determines industrial competitiveness and national security. What we need is not just research and development, but an implementation system that connects technology to the market, manufacturing sites, job creation, and industrial structure innovation. When the government, industry, and research institutes work closely together to accelerate the "bio-manufacturing transition," synthetic biology will become a new growth engine for the Korean economy.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Tae-Seok Oh, President of the Korea Institute of Science and Technology Planning and Evaluation
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.